Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Vi Lam
Institutions:
City Of Hope National Medical Center,
Oregon Health & Science University,
City of Hope
Observed institutions:
City Of Hope National Medical Center,
McDaniel College,
Oregon Health & Science University,
City of Hope,
OHSU Knight Cancer Institute
ORCID:
0000-0003-4578-3531
Observed ORCID:
0000-0003-4578-3531
OpenAlex ID:
A5021469964
Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma
2019
·
Taylor Hashiguchi
, Nur Bruss
, et al.
·
Molecular Cancer Therapeutics
·
71
Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX- Dependent Manner
2021
·
Tingting Liu
, Vi Lam
, et al.
·
Clinical Cancer Research
·
60
PDF
Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells
2020
·
Scott Best
, Vi Lam
, et al.
·
Leukemia
·
39
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
2022
·
Elana Thieme
, Tingting Liu
, et al.
·
Cell Death and Disease
·
27
PDF
T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
2023
·
Vi Lam
, Carly Roleder
, et al.
·
Molecular Cancer Therapeutics
·
22
PDF
Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia
2023
·
Xiaoguang Wang
, Canping Chen
, et al.
·
Leukemia
·
19
PDF
Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia
2021
·
Vi Lam
, Scott Best
, et al.
·
British Journal of Clinical Pharmacology
·
13
Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
2021
·
Adam S. Kittai
, Scott Best
, et al.
·
Haematologica
·
11
PDF
NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells
2021
·
Adam S. Kittai
, Olga V. Danilova
, et al.
·
Oncotarget
·
7
PDF
Pre-Clinical Activity of Amino-Alcohol Dimeric Naphthoquinones as Potential Therapeutics for Acute Myeloid Leukemia
2021
·
Dana Ferraris
, Rena Lapidus
, et al.
·
Anti-Cancer Agents in Medicinal Chemistry
·
5
Pharmacologic Inhibition of SUMO-Activating Enzyme (SAE) with TAK-981 Augments Interferon Signaling and Regulates T Cell Differentiation in Ex Vivo studies of Chronic Lymphocytic Leukemia (CLL)
2019
·
Vi Lam
, Scott R Best
, et al.
·
Blood
·
5
Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells
2020
·
Tingting Liu
, Fei Xu
, et al.
·
Blood
·
4
Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models
2020
·
Elana Thieme
, Vi Lam
, et al.
·
Blood
·
4
Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
2021
·
Alexey V. Danilov
, Vi Lam
, et al.
·
Blood
·
3
Pharmacologic Inhibition of SUMO-Activating Enzyme Potentiates Interferon Response and T Cell-Mediated Anti-Tumor Immunity in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Models
2021
·
Vi Lam
, Xiaoguang Wang
, et al.
·
Blood
·
2
Data from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
2023
·
Vi Lam
, Carly Roleder
, et al.
·
1
Abstract 938: Pharmacologic targeting Mcl-1 with AZD5991 induces apoptosis, suppresses mitochondrial respiration and overcomes ibrutinib resistance in non-Hodgkin lymphoma cells
2021
·
Tingting Liu
, Vi Lam
, et al.
·
Cancer Research
·
1
Figure 4 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
·
Carly Roleder
, Xiaofan Zhao
, et al.
Supplemental Table 1 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
·
Carly Roleder
, Xiaofan Zhao
, et al.
Supplemental Figure 5 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
·
Carly Roleder
, Xiaofan Zhao
, et al.
Supplemental Figure 4 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
·
Carly Roleder
, Xiaofan Zhao
, et al.
Figure 7 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
·
Carly Roleder
, Xiaofan Zhao
, et al.
Supplemental Figure 7 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
·
Carly Roleder
, Xiaofan Zhao
, et al.
Figure 1 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
·
Carly Roleder
, Xiaofan Zhao
, et al.
Supplemental Figure 3 from Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
2026
·
Carly Roleder
, Xiaofan Zhao
, et al.
Show more works
View as search
Works count:
102
Citation count:
294
H-index:
8
I10-index:
8
Year
Topic
Type